Full Text
Official text as published. Use Ctrl+F / Cmd+F to search within the document.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9061 Introduced in House (IH)]
<DOC>
119th CONGRESS
2d Session
H. R. 9061
To amend title XIX of the Social Security Act to require the Secretary
of Health and Human Services to issue guidance to States on which tests
for the screening and early detection of preeclampsia may be covered
under the Medicaid program and the Children's Health Insurance Program.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 29, 2026
Mr. Kean (for himself, Ms. Kelly of Illinois, Mrs. Kiggans of Virginia,
and Ms. Clarke of New York) introduced the following bill; which was
referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend title XIX of the Social Security Act to require the Secretary
of Health and Human Services to issue guidance to States on which tests
for the screening and early detection of preeclampsia may be covered
under the Medicaid program and the Children's Health Insurance Program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Preeclampsia Risk Evaluation and
Evidence-based Management through Personalized Testing Act'' or the
``PREEMPT Act''.
SEC. 2. FINDINGS.
Congress finds the following:
(1) According to the Centers for Disease Control and
Prevention, preeclampsia affects approximately 5 to 8 percent
of pregnancies globally, with 70,000 maternal deaths and
500,000 fetal deaths each year in the United States.
(2) In the United States, Black women are at least three
times more likely to die due to a pregnancy-related cause when
compared to White women.
(3) Preeclampsia and related cardiovascular and
hypertensive disorders of pregnancy are one of the leading
causes of maternal mortality and morbidity in the United
States, contributing to up to 15 percent of all maternal
deaths, particularly in States with the highest-risk
populations and in low resource settings.
(4) Preeclampsia is a major contributor to preterm births,
accounting for about 15 to 20 percent of all preterm deliveries
in the United States.
(5) The annual economic burden of preeclampsia in the
United States exceeds $2 billion, including both direct health
care costs to mother and baby, and indirect losses due to long-
term health complications and lost productivity.
(6) Risk factors for preeclampsia include maternal age,
pre-existing diabetes, pregnancies with multiples, chronic
hypertension, obesity, multiple pregnancies, and certain
autoimmune diseases, all of which can increase the likelihood
of developing this condition.
(7) Women who develop preeclampsia during pregnancy have an
elevated risk of long-term cardiovascular complications,
including chronic hypertension, heart disease and stroke.
SEC. 3. GUIDANCE ON MEDICAID COVERAGE OF PREECLAMPSIA SCREENING AND
DETECTION TESTS.
Title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) is
amended by inserting after section 1948 the following new section:
``SEC. 1949. GUIDANCE AND TECHNICAL ASSISTANCE WITH RESPECT TO COVERAGE
OF PREECLAMPSIA SCREENING AND DETECTION TESTS.
``(a) Guidance.--Not later than the date that is 180 days after the
date of the enactment of this section, the Secretary shall issue
guidance to States and, as appropriate, medicaid managed care
organizations, on--
``(1) best practices for improving outcomes for pregnant
women with preeclampsia who are eligible for and receiving
medical assistance under a State plan (or waiver of such plan)
under this title or a State child health plan (or waiver of
such plan) under title XXI through early screening, detection,
and management; and
``(2) which tests for the early detection of preeclampsia
may be furnished to such pregnant women as medical assistance
under such a State plan (or waiver) or such a State child
health plan (or waiver), including whether the biomarker tests
described in subsection (c) may be so furnished.
``(b) Technical Assistance.--
``(1) In general.--The Secretary shall, not later than 30
days after receipt of a request from a State for technical
assistance with respect to determining whether a State plan or
State child health plan may provide medical assistance for a
specific test for the early detection of preeclampsia,
including a biomarker test described in subsection (c), provide
such technical assistance to such State.
``(2) Rule of construction.--Nothing in this subsection
shall be construed as creating a requirement for a State to
request or receive the technical assistance described in
paragraph (1) as a condition of providing medical assistance
for a specific test for the early detection of preeclampsia, or
of receiving Federal financial participation for such medical
assistance.
``(c) Biomarker Tests To Be Considered.--For purposes of this
section, the Secretary shall consider advanced biomarker tests for the
early detection of preeclampsia, including any such test that is
regulated and cleared under the Federal Food, Drug, and Cosmetic Act as
a device (as defined in section 201(h) of such Act), and any such
laboratory-developed testing service furnished by a clinical laboratory
that is certified under section 353 of the Public Health Service Act to
perform high-complexity testing.''.
<all>